Aeolus Pharmaceuticals begins study of AEOL 10150 for Lou Gehrig's disease

By Jennifer Chiou

New York, Oct. 19 - Aeolus Pharmaceuticals, Inc. announced the start of its follow-on Phase I multiple-dose study of AEOL 10150 in patients diagnosed with amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease.

"We continue to remain very positive and excited about the prospects for AEOL 10150 as a potential therapeutic not only for patients diagnosed with ALS, but also for patients with other neurological diseases as well as radiation-related disorders," chief executive officer Richard P. Burgoon, Jr. said in a news release.

No serious adverse events have been reported after the first three ALS patients in the initial six-patient cohort received 40 mg of AEOL 10150 or placebo twice-daily for six days, followed by a single injection of 40 mg on the seventh day.

Aeolus said it expects to complete the multiple dose study within the fourth quarter or in the first quarter of 2006.

After completion of the study, the company plans to submit a request for a special protocol assessment to review plans with the FDA to conduct a Phase II/III study for a new drug application.

Based in Laguna Niguel, Calif., Aeolus develops therapeutic agents based on its small molecule catalytic antioxidants for neurodegenerative and other neurological disorders as well as radiation oncology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.